The U.S. Food and Drug Administration (FDA) has approved SKINVIVE by Juvéderm for reducing horizontal neck lines and improving neck appearance in adults aged 21 years and older, Allergan Aesthetics, an AbbVie company, announced on Monday.
The approval makes SKINVIVE by Juvéderm the first and only hyaluronic acid injectable approved specifically to reduce neck wrinkles while helping the skin retain its natural moisture.
The decision expands the role of injectable aesthetic treatments beyond the face, addressing growing consumer demand for neck rejuvenation and skin quality improvements in an area often associated with visible signs of ageing.
Targeting “tech-neck” and age-related wrinkles
According to Allergan Aesthetics, horizontal neck lines can develop due to natural ageing, sun damage, weight loss, or repeated downward head positioning while using phones, tablets and books, commonly referred to as “tech-neck”.
The company said SKINVIVE by Juvéderm is designed to improve the appearance of the neck by helping the skin retain moisture, softness and smoothness. The minimally invasive treatment is administered through an ultrafine needle or cannula and contains lidocaine, a local anaesthetic intended to improve patient comfort during the procedure.
Results can last up to six months with optimal treatment, according to the company.
“This approval expands our portfolio of lower face and neck treatment options and gives patients and aesthetic providers a first-of-its-kind treatment option for improving neck skin quality and reducing the appearance of neck lines,” said Darin Messina, Senior Vice President, Aesthetics Research and Development, AbbVie.
Clinical trial results
The approval was based on findings from a randomised, multicentre, evaluator-blinded and controlled clinical study.
A randomised clinical trial assigns participants to treatment groups by chance, while an evaluator-blinded study means the assessors do not know which treatment participants received.
According to the study, 74.8% of participants treated with SKINVIVE by Juvéderm achieved a clinically significant improvement in horizontal neck lines one month after treatment, as measured using the Allergan Transverse Neck Lines Scale.
Most participants maintained improvement through six months, with 66% continuing to show at least a one-point reduction in neck-line severity.
Participants who demonstrated improvement in overall appearance scores remained consistently high throughout the study period.
Safety and availability
The most commonly reported side effects included redness, bruising, tenderness, swelling, firmness, itching and discolouration at injection sites. The company said these effects were generally mild and resolved within two weeks.
As part of the approval, the FDA has required Allergan Aesthetics to provide training for healthcare professionals before they can administer the treatment.
The company expects SKINVIVE by Juvéderm for neck appearance improvement to become broadly available in the United States later this year. The approval marks the second FDA-authorised use of SKINVIVE by Juvéderm, which was first approved in 2023 to improve cheek skin smoothness in adults.
